Drug therapy in renal failure.

No abstract is available for this paper.

• Publication year

  1980

• Venue

  Annual Review of Pharmacology and Toxicology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1146/ANNUREV.PA.20.040180.000401PMID 6992702
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Determination of furosemide in blood plasma and its binding to proteins in normal plasma and in plasma from patients with acute renal failure.

  2009cited by this paper
• Kinetics of diphenylhydantoin in uraemic patients: Consequences of decreased plasma protein binding

  2004cited by this paper
• The effect of renal transplantation on plasma protein binding.

  1979cited by this paper
• The Effect of Disease on the Response to Drugs

  1979cited by this paper
• Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease.

  1978cited by this paper
• Serum and plasma concentrations of clindamycin following a single intramuscular injection of clindamycin phosphate in maintenance haemodialysis patients and normal subjects

  1978cited by this paper
• 2507 – CLINICAL PHARMACOLOGY OF N-ACETYLPROCAINAMIDE (NAPA), THE MAJOR METABOLITE OF PROCAINAMIDE IN MAN

  1978cited by this paper
• Steady‐state serum levels of quinidine and active metabolites in cardiac patients with varying degrees of renal function

  1978cited by this paper
• Dose‐ranging trial of N‐acetylprocainamide in patients with premature ventricular contractions

  1977cited by this paper
• Drug administration in renal failure.

  1977cited by this paper
• Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer.

  1977cited by this paper
• Studies on digitalis; XI. Digitoxin metabolism in patients with impaired renal function

  1977cited by this paper
• The biotransformation of drugs in renal failure.

  1977cited by this paper
• Alteration of plasma albumin in relation to decreased drug binding in uremia

  1977cited by this paper
• Alteration of plasma albumin in relation to decreased drug binding in uremia.

  1977cited by this paper
• Guidelines for drug therapy in renal failure.

  1977cited by this paper
• Plasma Protein Binding of Phenytoin and Warfarin in Patients Undergoing Renal Transplantation

  1977cited by this paper
• Cumulation of N‐acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function

  1977cited by this paper
• The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function.

  1977cited by this paper
• Drug Dosage in Renal Disease

  1976cited by this paper
• Correction of protein binding defect in uremic sera by charcoal treatment.

  1976cited by this paper
• Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors.

  1976cited by this paper
• Pharmacokinetics of acetaminophen elimination by anephric patients.

  1976cited by this paper
• Pharmacologically Active Drug Metabolites: Therapeutic and Toxic Activities, Plasma and Urine Data in Man, Accumulation in Renal Failure

  1976cited by this paper
• Pharmacokinetics and Effects of Propranolol in Terminal Uraemic Patients and in Patients Undergoing Regular Dialysis Treatment

  1976cited by this paper
• Influence of uremia and hemodialysis on the turnover and metabolic effects of glucagon.

  1976cited by this paper
• Effect of renal transplantation on protein binding of drugs in serum of donor and recipient

  1976cited by this paper
• Biotransformation and excretion of lorazepam in patients with chronic renal failure.

  1976cited by this paper
• Pentobarbital elimination in patients with poor renal function

  1976cited by this paper
• The Binding of Drugs to Plasma Proteins from Patients with Poor Renal Function

  1976cited by this paper
• Clinical use of drugs in renal failure

  1976cited by this paper
• Commentary: a physiological approach to hepatic drug clearance.

  1975cited by this paper
• The plasma half-life of antipyrine in chromic uraemic and normal subjects.

  1975cited by this paper
• Pharmacokinetics of drugs in patients with the nephrotic syndrome.

  1975cited by this paper
• Clofibrate-induced muscle damage in patients with chronic renal failure.

  1975cited by this paper
• Pharmacokinetics and metabolism of lidocaine in patients with renal failure

  1975cited by this paper
• Absolute bioavailability in man of N‐acetylprocainamide determined by a novel stable isotope method

  1975cited by this paper
• Pharmacokinetics of oral propranolol in chronic renal disease

  1974cited by this paper
• Quinidine elimination in patients with congestive heart failure or poor renal function.

  1974cited by this paper
• Kinetics of salicylate elimination by anephric patients.

  1974cited by this paper
• Studies on digitalis; II. The influence of impaired renal function on the renal excretion of digitoxin and its cardioactive metabolites

  1974cited by this paper
• Elimination of isoniazid in patients with impaired renal function.

  1973cited by this paper
• PHARMACOKINETIC CONSEQUENCES OF PLASMA PROTEIN BINDING OF DRUGS

  1973cited by this paper
• The metabolism of antipyrine in patients with chronic renal failure.

  1973cited by this paper
• Isoniazid dosage in patients with renal failure.

  1973cited by this paper
• The effect of haemodialysis on the binding capacity of albumin.

  1973cited by this paper
• Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans.

  1973cited by this paper
• The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin.

  1972cited by this paper
• Pharmacodynamics of Propranolol in Renal Failure

  1972cited by this paper
• Pharmacokinetics and biotransformation of chlorpropamide in man

  1972cited by this paper
• The rate of procaine hydrolysis in serum of normal subjects and diseased patients

  1972cited by this paper
• Oxidative drug metabolism in liver microsomes from uremic rats.

  1972cited by this paper
• Diphenylhydantoin metabolism in uremia.

  1971cited by this paper
• Effect of renal disease on renal uptake and excretion of insulin in man.

  1970cited by this paper
• Metabolism of xylitol in healthy subjects and patients with renal disease.

  1970cited by this paper
• Rate of drug metabolism in obese volunteers before and during starvation and in azotemic patients.

  1969cited by this paper
• The metabolism of phenacetin in patients with renal disease

  1969cited by this paper
• Pulmonary tuberculosis in patient on intermittent haemodialysis.

  1968cited by this paper
• Renal clearance of oxipurinol, the chief metabolite of allopurinol.

  1968cited by this paper
• Carbohydrate metabolism in uremia.

  1968cited by this paper
• The influence of renal disease on the insulin I-131 disappearance curve in man.

  1967cited by this paper
• Influence of renal insufficiency on the excretion of chloroquine, phenobarbital, phenothiazines and methacycline.

  1967cited by this paper
• THE METABOLISM OF METHYLDOPA IN HYPERTENSIVE HUMAN SUBJECTS.

  1964cited by this paper
• Histamine metabolism in human disease.

  1960cited by this paper
• Persistence of antibiotics in blood of patients with acute renal failure. II. Chloramphenicol and its metabolic products in the blood of patients with severe renal disease or hepatic cirrhosis.

  1959cited by this paper
• Metabolism of free and conjugated 17-hydroxycorticosteroids in subjects with uremia.

  1958cited by this paper
• Barbiturate narcosis in uraemia.

  1955cited by this paper

• Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children

  2015cites this paper
• Handling of Drugs in Children with Abnormal Renal Function

  2009cites this paper
• Geriatric pharmacology.

  2005cites this paper
• FHD: An Index to Evaluate Drug Elimination by Hemodialysis

  2005cites this paper
• Chapter 4 – Pharmacologic Principles

  2004cites this paper
• Pharmacokinetics of nitrendipine in terminal renal failure

  2004influential citation
• Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure

  2004cites this paper
• Practical Aspects of Drug Evaluation and Response

  2003cites this paper
• Mechanisms and clinical implications of renal drug excretion*

  2001cites this paper
• Host Defenses and Infectious Complications in Maintenance Hemodialysis Patients

  1996cites this paper
• Pharmacokinetics and Dialyzability of Sulindac and Metabolites in Patients with End‐Stage Renal Failure

  1993cites this paper
• Drug prescribing for patients with changing renal function.

  1992cites this paper
• The Pharmacokinetics of Racemic Verapamil in Patients with Impaired Renal Function

  1991cites this paper
• Pharmacokinetics of Cefprozil in Healthy Subjects and Patients with Hepatic Impairment

  1991cites this paper
• Emergencies in continuous dialysis patients: diagnosis and management.

  1990cites this paper
• The Effects of Renal Function on the Disposition of Isradipine

  1988cites this paper
• Antibiotikatherapie bei Niereninsuffizienz und Störungen der Leberfunktion

  1988cites this paper
• Arzneitherapie bei renaler Insuffizienz

  1988cites this paper
• Guide to Drug Dosage in Renal Failure

  1988cites this paper
• Altered S(--)-propranolol disposition in bilateral ureter-ligated rats.

  1987cites this paper
• The disposition of cytotoxic drugs in the elderly.

  1987cites this paper
• Current status of plasmapheresis in toxicology.

  1986cites this paper
• The plasma protein binding of metoclopramide in health and renal disease.

  1986cites this paper
• Nitrendipine kinetics in normal and impaired renal function

  1985cites this paper
• Verapamil kinetics during maintenance hemodialysis.

  1985cites this paper
• Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man.

  1985cites this paper
• Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. I. An application of pharmacokinetic model for reversible metabolism.

  1985cites this paper
• The Urinary System

  1984cites this paper
• Effect of renal impairment and hemodialysis on lorazepam kinetics

  1984cites this paper
• Cortisol binding in uremic plasma. II. Decreased cortisol binding to albumin.

  1984cites this paper
• Drug prescribing in renal failure: dosing guidelines for adults.

  1983cites this paper
• measurements of total drug plasma concentration.

  1983cites this paper
• Drug-protein conjugates--IV. The effect of acute renal failure on the disposition of [14C]captopril in the rat.

  1983cites this paper
• Elimination of amphotericin B in impaired renal function

  1983cites this paper
• Pharmacokinetics of brotizolam in renal failure.

  1983cites this paper
• Dental care for patients with renal failure and renal transplants.

  1982cites this paper
• Glucuronidation and disposition of drug glucuronides in patients with renal failure. A review.

  1982cites this paper
• Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function.

  1982cites this paper
• Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs.

  1982cites this paper
• Drugs and the Kidney

  1981cites this paper
• [Influence of disease on the metabolism and effects of drugs in man].

  1980cites this paper